OTCM
TBPMQ
Market cap0USD
May 27, Last price
0.00USD
Name
Tetra Bio Pharma Inc
Chart & performance
P/E
0.00
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0
Net income
-52m
L+97.06%
CFO
-25m
L+28.72%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Orléans, Canada, Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on discovering and developing cannabinoid-based medications. Their efforts span several therapeutic areas, including inflammation, pain management, ophthalmology, and oncology. The company's pipeline features various drug candidates: PLENITUDE is being developed for cancer-related pain in advanced patients, while REBORN addresses breakthrough cancer pain. Reduvo is designed to combat chemotherapy-induced nausea and vomiting. ARDS-003 targets sepsis and the prevention of acute respiratory distress syndrome, and SERENITY aims to treat cancer cachexia. Furthermore, Tetra Bio-Pharma is advancing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma.
Key people
Chief Financial Officer · since 2019
Richard Giguere
Executive Vice President - Commercial Operations · since 2018
Melanie Kelly
Chief Scientific Officer · since 2019
Robert Bechard
Vice President, Finance and Business Development · since 2017
Aurelia De Pauw
Vice President - Clinical Programs and Medical Affairs · since 2019
Ryan Brown
Vice President - Business Development · since 2016
Denis Courchesne
Vice President of Sales · since 2017
Steve Neron
Senior Vice President - Marketing and Medical Affairs · since 2018
Edward Miller
Vice President of Investor Relations & Corporate Communications · since 2017
Charles Campbell
Research Scientist
Randy Ringuette
Research Scientist
Director · since 2017
Robert Brouillette
Director
Benoit Chotard
Director · since 2018
Director · since 2017
Gregory John Drohan
Independent Director · since 2018
Headquarters & legal address
50 O'Connor Street, Suite 1600
Ottawa, ON K1P 6L2
CA
Ottawa, ON K1P 6L2
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||